Emerging paradigms in exploring the interactions among diet, probiotics, and cancer immunotherapeutic response

作者：Shi Huang, Chengyong He, Jiufeng Li, Yi‐Zhou Gao, Zuoyun Wang, Yongjun Wei · 发表于：The Innovation · 年份：2023 · DOI：10.1016/j.xinn.2023.100456 · 被引用次数：21 · 研究领域：Gut microbiota and health、Tryptophan and brain disorders、Cancer Immunotherapy and Biomarkers

In the new issue of Cell, Dr. Meisel’s team characterized how the orally administrated probiotic bacteria Lactobacillus reuteri (Lr) translocated from the gut to tumors in mice with melanoma.1 Furthermore, its production of a compound called indole-3-aldehyde (I3A) derived from dietary tryptophan directly stimulates immune cells to make cancer immunotherapy more effective (Figure 1A). Here, we highlight and comment on the essential findings and provide our insights into the emerging research paradigm for future exploration of novel anti-tumor probiotics and underlying mechanisms.